Muscle dysfunction in chronic obstructive pulmonary disease: Update on causes and biological findings

Journal of Thoracic Disease

Volumn 7, Issue 10, 2015, Pages E418-E438

  Gea, Joaquim ^a   Pascual, Sergi ^a   Casadevall, Carme ^a   Orozco Levi, Mauricio ^a   Barreiro, Esther ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Deconditioning; Hyperinflation; Muscle dysfunction; Proteostasis; Systemic inflammation

Indexed keywords

C REACTIVE PROTEIN;

AGING; BREATHING; CELL DENSITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; DISEASE ASSOCIATION; DRUG EFFECT; EPIGENETICS; EXERCISE; GAS EXCHANGE; HUMAN; MITOCHONDRION; MUSCLE BLOOD VESSEL; MUSCLE CELL; MUSCLE DISEASE; MUSCLE INJURY; MUSCLE REGENERATION; MYOSITIS; NITROSATIVE STRESS; NONHUMAN; NUTRITIONAL DEFICIENCY; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; SATELLITE CELL; SMOKING; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84947422196     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2015.08.04     Document Type: Review

References (254)

1. Carroll SB. Genetics and the making of Homo sapiens. Nature 2003;422:849-57.
2. Kibler WB. Normal shoulder mechanics and function. Instr Course Lect 1997;46:39-42.
3. Vaughan CL. Theories of bipedal walking: an odyssey. J Biomech 2003;36:513-23.
4. Edwards RHT, Faulkner JA. Structure and function of the respiratory muscles. In: Roussos C, editor. The Thorax. New York: Marcel Dekker Inc., 1995:185-217.
5. Macklem PT. The act of breathing. In: Roussos C, editor. The thorax. New York: Marcel Dekker Inc., 1995:445-56.
6. Derenne JP, Macklem PT, Roussos C. The respiratory muscles: mechanics, control, and pathophysiology. Am Rev Respir Dis 1978;118:119-33.
7. De Troyer A, Farkas G. Mechanics of the parasternal intercostals in prone dogs: statics and dynamics. J Appl Physiol (1985) 1993;74:2757-62.
8. De Troyer A. Interaction between the canine diaphragm and intercostal muscles in lung expansion. J Appl Physiol (1985) 2005;98:795-803.
9. De Troyer A, Kirkwood PA, Wilson TA. Respiratory action of the intercostal muscles. Physiol Rev 2005;85:717-56.
10. De Troyer A, Leduc D. Effect of diaphragmatic contraction on the action of the canine parasternal intercostals. J Appl Physiol (1985) 2006;101:169-75.
11. Hug F, Raux M, Prella M, et al. Optimized analysis of surface electromyograms of the scalenes during quiet breathing in humans. Respir Physiol Neurobiol 2006;150:75-81.
12. Legrand A, Schneider E, Gevenois PA, et al. Respiratory effects of the scalene and sternomastoid muscles in humans. J Appl Physiol (1985) 2003;94:1467-72.
13. Decramer M. Hyperinflation and respiratory muscle interaction. Eur Respir J 1997;10:934-41.
14. Orozco-Levi M, Gea J, Monells J, et al. Activity of latissimus dorsi muscle during inspiratory threshold loads. Eur Respir J 1995;8:441-5.
15. Bellemare F, Bono D, D'Angelo E. Electrical and mechanical output of the expiratory muscles in anesthetized dogs. Respir Physiol 1991;84:171-83.
16. Chang AB. The physiology of cough. Paediatr Respir Rev 2006;7:2-8.
17. Fuller D, Sullivan J, Fregosi RF. Expiratory muscle endurance performance after exhaustive submaximal exercise. J Appl Physiol (1985) 1996;80:1495-502.
18. Epstein SK. An overview of respiratory muscle function. Clin Chest Med 1994;15:619-39.
19. Gea J, Barreiro E, Orozco-Levi M. Skeletal muscle adaptation to disease states. In: Bottinelli R, Reggiani C, editors. Skeletal Muscle Plasticity in Health and Disease: From genes to whole muscle. Dordrecht: Springer, 2006:315-60.
20. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. Accessed July 2015. Available online: http://www.goldcopd.org/
21. Orozco-Levi M, Garcia-Aymerich J, Villar J, et al. Wood smoke exposure and risk of chronic obstructive pulmonary disease. Eur Respir J 2006;27:542-6.
22. Evans RA, Morgan MD. The systemic nature of chronic lung disease. Clin Chest Med 2014;35:283-93.
23. Freixa X, Portillo K, Paré C, et al. Echocardiographic abnormalities in patients with COPD at their first hospital admission. Eur Respir J 2013;41:784-91.
24. Maltais F, Decramer M, Casaburi R, et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014;189:e15-62.
25. Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med 2014;35:71-86.
26. Romme EA, Smeenk FW, Rutten EP, et al. Osteoporosis in chronic obstructive pulmonary disease. Expert Rev Respir Med 2013;7:397-410.
27. Bosmann M, Ward PA. The inflammatory response in sepsis. Trends Immunol 2013;34:129-36.
28. Maloney PJ. Sepsis and septic shock. Emerg Med Clin North Am 2013;31:583-600.
29. de Jong HK, van der Poll T, Wiersinga WJ. The systemic pro-inflammatory response in sepsis. J Innate Immun 2010;2:422-30.
30. Wouters E. COPD: from obstructive lung disease to chronic systemic inflammatory syndrome? Pneumologie 2009;63 Suppl 2:S107-12.
31. Kirdar S, Serter M, Ceylan E, et al. Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. Scand J Clin Lab Invest 2009;69:219-24.
32. Barreiro E, Gea J. Respiratory and Limb Muscle Dysfunction in COPD. COPD 2015;12:413-26.
33. Rochester DF, Braun NM, Arora NS. Respiratory muscle strength in chronic obstructive pulmonary disease. Am Rev Respir Dis 1979;119:151-4.
34. Similowski T, Yan S, Gauthier AP, et al. Contractile properties of the human diaphragm during chronic hyperinflation. N Engl J Med 1991;325:917-23.
35. Goldman MD, Grassino A, Mead J, et al. Mechanics of the human diaphragm during voluntary contraction: dynamics. J Appl Physiol Respir Environ Exerc Physiol 1978;44:840-8.
36. Westerbald H, Lännergren J, Allen DG. Fatigue of striated muscles: Metabolic aspects. Chapter 6. In: Roussos C, editor. The Thorax. New York: Marcel Dekker Inc., 1995:219-34.
37. Di Francia M, Barbier D, Mege JL, et al. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150:1453-5.
38. Rahman I, Morrison D, Donaldson K, et al. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996;154:1055-60.
39. Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7:e37483
40. Schols AM. Nutrition in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2000;6:110-5.
41. Remels AH, Gosker HR, Langen RC, et al. The mechanisms of cachexia underlying muscle dysfunction in COPD. J Appl Physiol (1985) 2013;114:1253-62.
42. Gea J, Agustí A, Roca J. Pathophysiology of muscle dysfunction in COPD. J Appl Physiol (1985) 2013;114:1222-34.
43. Barreiro E, de la Puente B, Minguella J, et al. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:1116-24.
44. Casadevall C, Coronell C, Ramírez-Sarmiento AL, et al. Upregulation of pro-inflammatory cytokines in the intercostal muscles of COPD patients. Eur Respir J 2007;30:701-7.
45. Puig-Vilanova E, Aguiló R, Rodríguez-Fuster A, et al. Epigenetic mechanisms in respiratory muscle dysfunction of patients with chronic obstructive pulmonary disease. PLoS One 2014;9:e111514.
46. Bellemare F, Grassino A. Force reserve of the diaphragm in patients with chronic obstructive pulmonary disease. J Appl Physiol Respir Environ Exerc Physiol 1983;55:8-15.
47. Barreiro E, Bustamante V, Cejudo P, et al. Guidelines for the Evaluation and Treatment of Muscle Dysfunction in Patients With Chronic Obstructive Pulmonary Disease. Arch Bronconeumol 2015;51:384-95.
48. Levine S, Kaiser L, Leferovich J, et al. Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med 1997;337:1799-806.
49. Gea JG. Myosin gene expression in the respiratory muscles. Eur Respir J 1997;10:2404-10.
50. Clanton TL, Levine S. Respiratory muscle fiber remodeling in chronic hyperinflation: dysfunction or adaptation? J Appl Physiol (1985) 2009;107:324-35
51. Orozco-Levi M, Gea J, Lloreta JL, et al. Subcellular adaptation of the human diaphragm in chronic obstructive pulmonary disease. Eur Respir J 1999;13:371-8.
52. Campbell JA, Hughes RL, Sahgal V, et al. Alterations in intercostal muscle morphology and biochemistry in patients with obstructive lung disease. Am Rev Respir Dis 1980;122:679-86.
53. Caron MA, Debigaré R, Dekhuijzen PN, et al. Comparative assessment of the quadriceps and the diaphragm in patients with COPD. J Appl Physiol (1985) 2009;107:952-61.
54. Sanchez J, Derenne JP, Debesse B, et al. Typology of the respiratory muscles in normal men and in patients with moderate chronic respiratory diseases. Bull Eur Physiopathol Respir 1982;18:901-14.
55. Hards JM, Reid WD, Pardy RL, et al. Respiratory muscle fiber morphometry. Correlation with pulmonary function and nutrition. Chest 1990;97:1037-44.
56. Levine S, Nguyen T, Friscia M, et al. Parasternal intercostal muscle remodeling in severe chronic obstructive pulmonary disease. J Appl Physiol (1985) 2006;101:1297-302.
57. Gea J, Hamid Q, Czaika G, et al. Expression of myosin heavy-chain isoforms in the respiratory muscles following inspiratory resistive breathing. Am J Respir Crit Care Med 2000;161:1274-8.
58. Zhu E, Petrof BJ, Gea J, et al. Diaphragm muscle fiber injury after inspiratory resistive breathing. Am J Respir Crit Care Med 1997;155:1110-6.
59. Orozco-Levi M, Lloreta J, Minguella J, et al. Injury of the human diaphragm associated with exertion and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1734-9.
60. Lloreta J, Orozco M, Gea J, et al. Selective diaphragmatic mitochondrial abnormalities in a patient with marked air flow obstruction. Ultrastruct Pathol 1996;20:67-71.
61. Levine S, Nguyen T, Kaiser LR, et al. Human diaphragm remodeling associated with chronic obstructive pulmonary disease: clinical implications. Am J Respir Crit Care Med 2003;168:706-13.
62. Dodd DS, Brancatisano T, Engel LA. Chest wall mechanics during exercise in patients with severe chronic air-flow obstruction. Am Rev Respir Dis 1984;129:33-8.
63. Ninane V, Rypens F, Yernault JC, et al. Abdominal muscle use during breathing in patients with chronic airflow obstruction. Am Rev Respir Dis 1992;146:16-21.
64. Ninane V, Yernault JC, de Troyer A. Intrinsic PEEP in patients with chronic obstructive pulmonary disease. Role of expiratory muscles. Am Rev Respir Dis 1993;148:1037-42.
65. O'Donnell DE, Sanii R, Anthonisen NR, et al. Expiratory resistive loading in patients with severe chronic air-flow limitation. An evaluation of ventilatory mechanics and compensatory responses. Am Rev Respir Dis 1987;136:102-7.
66. Gorini M, Misuri G, Duranti R, et al. Abdominal muscle recruitment and PEEPi during bronchoconstriction in chronic obstructive pulmonary disease. Thorax 1997;52:355-61.
67. Mota S, Güell R, Barreiro E, et al. Relationship between expiratory muscle dysfunction and dynamic hyperinflation in advanced chronic obstructive pulmonary disease. Arch Bronconeumol 2009;45:487-95.
68. Ramírez-Sarmiento A, Orozco-Levi M, Barreiro E, et al. Expiratory muscle endurance in chronic obstructive pulmonary disease. Thorax 2002;57:132-6.
69. Gosselink R, Troosters T, Decramer M. Distribution of muscle weakness in patients with stable chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2000;20:353-60.
70. Arnold JS, Thomas AJ, Kelsen SG. Length-tension relationship of abdominal expiratory muscles: effect of emphysema. J Appl Physiol (1985) 1987;62:739-45.
71. Ferrer A, Orozco-Levi M, Gea J, et al. Mechanical and metabolic reproducibility of resistance test of expiratory muscles with incremental threshold loading. Arch Bronconeumol 2000;36:303-12.
72. Hamilton AL, Killian KJ, Summers E, et al. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med 1995;152:2021-31.
73. Coronell C, Orozco-Levi M, Méndez R, et al. Relevance of assessing quadriceps endurance in patients with COPD. Eur Respir J 2004;24:129-36.
74. Castagna O, Boussuges A, Vallier JM, et al. Is impairment similar between arm and leg cranking exercise in COPD patients? Respir Med 2007;101:547-53.
75. Killian KJ, Leblanc P, Martin DH, et al. Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. Am Rev Respir Dis 1992;146:935-40.
76. Killian KJ, Summers E, Jones NL, et al. Dyspnea and leg effort during incremental cycle ergometry. Am Rev Respir Dis 1992;145:1339-45.
77. Jones SE, Maddocks M, Kon SS, et al. Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax 2015;70:213-8.
78. Sala E, Roca J, Marrades RM, et al. Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:1726-34.
79. Evans RA, Kaplovitch E, Beauchamp MK, et al. Is quadriceps endurance reduced in COPD?: a systematic review. Chest 2015;147:673-84.
80. Eliason G, Abdel-Halim SM, Piehl-Aulin K, et al. Alterations in the muscle-to-capillary interface in patients with different degrees of chronic obstructive pulmonary disease. Respir Res 2010;11:97.
81. Hildebrand IL, Sylvén C, Esbjörnsson M, et al. Does chronic hypoxaemia induce transformations of fibre types? Acta Physiol Scand 1991;141:435-9.
82. Jakobsson P, Jorfeldt L, Brundin A. Skeletal muscle metabolites and fibre types in patients with advanced chronic obstructive pulmonary disease (COPD), with and without chronic respiratory failure. Eur Respir J 1990;3:192-6.
83. Jakobsson P, Jorfeldt L, Henriksson J. Metabolic enzyme activity in the quadriceps femoris muscle in patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;151:374-7.
84. Simard C, Maltais F, Leblanc P, et al. Mitochondrial and capillarity changes in vastus lateralis muscle of COPD patients: electron microscopy study. Med Sci Sports Exerc 1996;28:S95.
85. Satta A, Migliori GB, Spanevello A, et al. Fibre types in skeletal muscles of chronic obstructive pulmonary disease patients related to respiratory function and exercise tolerance. Eur Respir J 1997;10:2853-60.
86. Whittom F, Jobin J, Simard PM, et al. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc 1998;30:1467-74.
87. Maltais F, Simard AA, Simard C, et al. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med 1996;153:288-93.
88. Wuyam B, Payen JF, Levy P, et al. Metabolism and aerobic capacity of skeletal muscle in chronic respiratory failure related to chronic obstructive pulmonary disease. Eur Respir J 1992;5:157-62.
89. Natanek SA, Gosker HR, Slot IG, et al. Pathways associated with reduced quadriceps oxidative fibres and endurance in COPD. Eur Respir J 2013;41:1275-83.
90. Maltais F, Jobin J, Sullivan MJ, et al. Lower limb metabolic and hemodynamic responses during exercise in normal subjects and in COPD. J Appl Physiol 1998;84:1573-80.
91. Engelen MP, Schols AM, Does JD, et al. Exercise-induced lactate increase in relation to muscle substrates in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:1697-704.
92. Casaburi R, Patessio A, Ioli F, et al. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis 1991;143:9-18.
93. Hernández N, Orozco-Levi M, Belalcázar V, et al. Dual morphometrical changes of the deltoid muscle in patients with COPD. Respir Physiol Neurobiol 2003;134:219-29.
94. Gea JG, Pasto M, Carmona MA, et al. Metabolic characteristics of the deltoid muscle in patients with chronic obstructive pulmonary disease. Eur Respir J 2001;17:939-45.
95. Sato Y, Asoh T, Honda Y, et al. Morphologic and histochemical evaluation of muscle in patients with chronic pulmonary emphysema manifesting generalized emaciation. Eur Neurol 1997;37:116-21.
96. Shields GS, Coissi GS, Jimenez-Royo P, et al. Bioenergetics and intermuscular fat in chronic obstructive pulmonary disease-associated quadriceps weakness. Muscle Nerve 2015;51:214-21.
97. Gea J, Orozco-Levi M, Barreiro E, et al. Structural and functional changes in the skeletal muscles of COPD patients: the "compartments" theory. Monaldi Arch Chest Dis 2001;56:214-24.
98. Barreiro E, Schols AM, Polkey MI, et al. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax 2008;63:100-7.
99. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80.
100. Montes de Oca M, Torres SH, De Sanctis J, et al. Skeletal muscle inflammation and nitric oxide in patients with COPD. Eur Respir J 2005;26:390-7.
101. Schols AM, Buurman WA, Staal van den Brekel AJ, et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996;51:819-24.
102. Zhang J, Liu Y, Shi J, et al. Side-stream cigarette smoke induces dose-response in systemic inflammatory cytokine production and oxidative stress. Exp Biol Med (Maywood) 2002;227:823-9.
103. Salvi S, Blomberg A, Rudell B, et al. Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers. Am J Respir Crit Care Med 1999;159:702-9.
104. van Eeden SF, Tan WC, Suwa T, et al. Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM(10)). Am J Respir Crit Care Med 2001;164:826-30.
105. Nordskog BK, Fields WR, Hellmann GM. Kinetic analysis of cytokine response to cigarette smoke condensate by human endothelial and monocytic cells. Toxicology 2005;212:87-97.
106. Barreiro E, Peinado VI, Galdiz JB, et al. Cigarette smoke-induced oxidative stress: A role in chronic obstructive pulmonary disease skeletal muscle dysfunction. Am J Respir Crit Care Med 2010;182:477-88.
107. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax 2010;65:930-6.
108. Sauleda J, García-Palmer FJ, González G, et al. The activity of cytochrome oxidase is increased in circulating lymphocytes of patients with chronic obstructive pulmonary disease, asthma, and chronic arthritis. Am J Respir Crit Care Med 2000;161:32-5.
109. Gosker HR, Kubat B, Schaart G, et al. Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease. Eur Respir J 2003;22:280-5.
110. Rabinovich RA, Figueras M, Ardite E, et al. Increased tumour necrosis factor-alpha plasma levels during moderate-intensity exercise in COPD patients. Eur Respir J 2003;21:789-94.
111. Flores EA, Bistrian BR, Pomposelli JJ, et al. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. J Clin Invest 1989;83:1614-22.
112. Hall-Angerås M, Angerås U, Zamir O, et al. Interaction between corticosterone and tumor necrosis factor stimulated protein breakdown in rat skeletal muscle, similar to sepsis. Surgery 1990;108:460-6.
113. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000;109:288-95.
114. White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease . 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003;58:73-80.
115. Reid MB, Haack KE, Franchek KM, et al. Reactive oxygen in skeletal muscle. I. Intracellular oxidant kinetics and fatigue in vitro. J Appl Physiol (1985) 1992;73:1797-804.
116. Kobzik L, Reid MB, Bredt DS, et al. Nitric oxide in skeletal muscle. Nature 1994;372:546-8.
117. Stamler JS, Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol Rev 2001;81:209-237.
118. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996;271:C1424-37.
119. Tamir S, Burney S, Tannenbaum SR. DNA damage by nitric oxide. Chem Res Toxicol 1996;9:821-7.
120. Eiserich JP, Estévez AG, Bamberg TV, et al. Microtubule dysfunction by posttranslational nitrotyrosination of alpha-tubulin: a nitric oxide-dependent mechanism of cellular injury. Proc Natl Acad Sci U S A 1999;96:6365-70.
121. Supinski G. Free radical induced respiratory muscle dysfunction. Mol Cell Biochem 1998;179:99-110.
122. Parks DA, Granger DN. Ischemia-induced vascular changes: role of xanthine oxidase and hydroxyl radicals. Am J Physiol 1983;245:G285-9.
123. Barreiro E, Gea J, Corominas JM, et al. Nitric oxide synthases and protein oxidation in the quadriceps femoris of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2003;29:771-8.
124. Gosker HR, Bast A, Haenen GR, et al. Altered antioxidant status in peripheral skeletal muscle of patients with COPD. Respir Med 2005;99:118-25.
125. Gea J, Barreiro E, Hussain SNA. Differential oxidative stress and nitrosative stress profiles in respiratory and peripheral muscles of COPD patients. Proc Am Thorac Soc 2006;3:A26.
126. Koechlin C, Couillard A, Simar D, et al. Does oxidative stress alter quadriceps endurance in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2004;169:1022-7.
127. Barreiro E, Gea J, Matar G, et al. Expression and carbonylation of creatine kinase in the quadriceps femoris muscles of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2005;33:636-42.
128. Kondo H, Miura M, Nakagaki I, et al. Trace element movement and oxidative stress in skeletal muscle atrophied by immobilization. Am J Physiol 1992;262:E583-90.
129. Barreiro E, Gáldiz JB, Mariñán M, et al. Respiratory loading intensity and diaphragm oxidative stress: N-acetyl-cysteine effects. J Appl Physiol (1985) 2006;100:555-63.
130. Bloomfield SA. Changes in musculoskeletal structure and function with prolonged bed rest. Med Sci Sports Exerc 1997;29:197-206.
131. Maltais F, LeBlanc P, Simard C, et al. Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154:442-7.
132. Winkelman C. Inactivity and inflammation in the critically ill patient. Crit Care Clin 2007;23:21-34.
133. Le Bourdelles G, Viires N, Boczkowski J, et al. Effects of mechanical ventilation on diaphragmatic contractile properties in rats. Am J Respir Crit Care Med 1994;149:1539-44.
134. Díaz MC, Ospina-Tascón GA, Salazar C BC. Respiratory muscle dysfunction: a multicausal entity in the critically ill patient undergoing mechanical ventilation. Arch Bronconeumol 2014;50:73-7.
135. Deconinck N, Van Parijs V, Beckers-Bleukx G, et al. Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agents. Neuromuscul Disord 1998;8:186-92.
136. Polkey MI, Moxham J. Clinical aspects of respiratory muscle dysfunction in the critically ill. Chest 2001;119:926-39.
137. Schols AM, Ferreira IM, Franssen FM, et al. Nutritional assessment and therapy in COPD: a European Respiratory Society statement. Eur Respir J 2014;44:1504-20.
138. Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1791-7.
139. Schols AM, Broekhuizen R, Weling-Scheepers CA, et al. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005;82:53-9.
140. Puig-Vilanova E, Rodriguez DA, Lloreta J, et al. Oxidative stress, redox signaling pathways, and autophagy in cachectic muscles of male patients with advanced COPD and lung cancer. Free Radic Biol Med 2015;79:91-108.
141. Schols AM, Creutzberg EC, Buurman WA, et al. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1220-6.
142. Guenette JA, Chin RC, Cheng S, et al. Mechanisms of exercise intolerance in global initiative for chronic obstructive lung disease grade 1 COPD. Eur Respir J 2014;44:1177-87.
143. Garcia-Aymerich J, Gómez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011;66:430-7.
144. Coronell C, Orozco-Levi M, Gea J. COPD and body weight in a Mediterranean population. Clin Nutr 2002;21:437; author reply 437-8.
145. Gea J, Martínez-Llorens J, Barreiro E. Nutritional abnormalities in chronic obstructive pulmonary disease. Med Clin (Barc) 2014;143:78-84.
146. Deboeck G, Moraine JJ, Naeije R. Respiratory muscle strength may explain hypoxia-induced decrease in vital capacity. Med Sci Sports Exerc 2005;37:754-8.
147. Romer LM, Haverkamp HC, Amann M, et al. Effect of acute severe hypoxia on peripheral fatigue and endurance capacity in healthy humans. Am J Physiol Regul Integr Comp Physiol 2007;292:R598-606.
148. Pastoris O, Dossena M, Foppa P, et al. Modifications by chronic intermittent hypoxia and drug treatment on skeletal muscle metabolism. Neurochem Res 1995;20:143-50.
149. Brunelle JK, Chandel NS. Oxygen deprivation induced cell death: an update. Apoptosis 2002;7:475-82.
150. Gonzalez NC, Wood JG. Alveolar hypoxia-induced systemic inflammation: what low PO(2) does and does not do. Adv Exp Med Biol 2010;662:27-32.
151. Yun Z, Lin Q, Giaccia AJ. Adaptive myogenesis under hypoxia. Mol Cell Biol 2005;25:3040-55.
152. Aguar MC, Gea J, Aran X, et al. Modificaciones de la actividad mecánica del diafragma inducidas por la inhalación de CO2 en pacientes con EPOC. Arch Bronconeumol 1993;29:226-8.
153. Rafferty GF, Lou Harris M, Polkey MI, et al. Effect of hypercapnia on maximal voluntary ventilation and diaphragm fatigue in normal humans. Am J Respir Crit Care Med 1999;160:1567-71.
154. England BK, Chastain JL, Mitch WE. Abnormalities in protein synthesis and degradation induced by extracellular pH in BC3H1 myocytes. Am J Physiol 1991;260:C277-82.
155. Corwin EJ, Klein LC, Rickelman K. Predictors of fatigue in healthy young adults: moderating effects of cigarette smoking and gender. Biol Res Nurs 2002;3:222-33.
156. Morse CI, Wüst RC, Jones DA, et al. Muscle fatigue resistance during stimulated contractions is reduced in young male smokers. Acta Physiol (Oxf) 2007;191:123-9.
157. Wüst RC, Morse CI, de Haan A, et al. Skeletal muscle properties and fatigue resistance in relation to smoking history. Eur J Appl Physiol 2008;104:103-10.
158. Rom O, Kaisari S, Aizenbud D, et al. Sarcopenia and smoking: a possible cellular model of cigarette smoke effects on muscle protein breakdown. Ann N Y Acad Sci 2012;1259:47-53.
159. Petersen AM, Magkos F, Atherton P, et al. Smoking impairs muscle protein synthesis and increases the expression of myostatin and MAFbx in muscle. Am J Physiol Endocrinol Metab 2007;293:E843-8.
160. Goldberg AL, Goodman HM. Relationship between cortisone and muscle work in determining muscle size. J Physiol 1969;200:667-75.
161. Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:1958-64.
162. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab 1996;81:3469-75.
163. Karadag F, Ozcan H, Karul AB, et al. Sex hormone alterations and systemic inflammation in chronic obstructive pulmonary disease. Int J Clin Pract 2009;63:275-81.
164. Laghi F, Langbein WE, Antonescu-Turcu A, et al. Respiratory and skeletal muscles in hypogonadal men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:598-605.
165. Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003;46:76s-80s.
166. Scalvini S, Volterrani M, Vitacca M, et al. Plasma hormone levels and haemodynamics in patients with chronic obstructive lung disease. Monaldi Arch Chest Dis 1996;51:380-6.
167. Franssen FM, Sauerwein HP, Ackermans MT, et al. Increased postabsorptive and exercise-induced whole-body glucose production in patients with chronic obstructive pulmonary disease. Metabolism 2011;60:957-64.
168. Couillard A, Koechlin C, Cristol JP, et al. Evidence of local exercise-induced systemic oxidative stress in chronic obstructive pulmonary disease patients. Eur Respir J 2002;20:1123-9.
169. Couillard A, Maltais F, Saey D, et al. Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:1664-9.
170. Mercken EM, Hageman GJ, Langen RC, et al. Decreased exercise-induced expression of nuclear factor-?B-regulated genes in muscle of patients with COPD. Chest 2011;139:337-46.
171. Van Helvoort HA, Heijdra YF, Thijs HM, et al. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc 2006;38:1543-52.
172. Layec G, Haseler LJ, Richardson RS, et al. The effect of higher ATP cost of contraction on the metabolic response to graded exercise in patients with chronic obstructive pulmonary disease. J Appl Physiol (1985) 2012;112:1041-8.
173. Richardson RS, Leek BT, Gavin TP, et al. Reduced mechanical efficiency in chronic obstructive pulmonary disease but normal peak VO2 with small muscle mass exercise. Am J Respir Crit Care Med 2004;169:89-96.
174. Turan N, Kalko S, Stincone A, et al. A systems biology approach identifies molecular networks defining skeletal muscle abnormalities in chronic obstructive pulmonary disease. PLoS Comput Biol 2011;7:e1002129.
175. Barreiro E, Rabinovich R, Marin-Corral J, et al. Chronic endurance exercise induces quadriceps nitrosative stress in patients with severe COPD. Thorax 2009;64:13-9.
176. Rodriguez DA, Kalko S, Puig-Vilanova E, et al. Muscle and blood redox status after exercise training in severe COPD patients. Free Radic Biol Med 2012;52:88-94.
177. Abdellaoui A, Préfaut C, Gouzi F, et al. Skeletal muscle effects of electrostimulation after COPD exacerbation: a pilot study. Eur Respir J 2011;38:781-8.
178. Vermeeren MA, Schols AM, Wouters EF. Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. Eur Respir J 1997;10:2264-9.
179. Pitta F, Troosters T, Probst VS, et al. Physical activity and hospitalization for exacerbation of COPD. Chest 2006;129:536-44.
180. Ansari K, Keaney N, Taylor I, et al. Muscle weakness, health status and frequency of exacerbations in chronic obstructive pulmonary disease. Postgrad Med J 2012;88:372-6.
181. Vilaró J, Ramirez-Sarmiento A, Martínez-Llorens JM, et al. Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations. Respir Med 2010;104:1896-902.
182. Rehn TA, Munkvik M, Lunde PK, et al. Intrinsic skeletal muscle alterations in chronic heart failure patients: a disease-specific myopathy or a result of deconditioning? Heart Fail Rev 2012;17:421-36.
183. Morley JE. Sarcopenia in the elderly. Fam Pract 2012;29 Suppl 1:i44-i48.
184. Budui SL, Rossi AP, Zamboni M. The pathogenetic bases of sarcopenia. Clin Cases Miner Bone Metab 2015;12:22-6.
185. Crescenzo R, Bianco F, Mazzoli A, et al. Skeletal muscle mitochondrial energetic efficiency and aging. Int J Mol Sci 2015;16:10674-85.
186. Denison HJ, Cooper C, Sayer AA, et al. Prevention and optimal management of sarcopenia: a review of combined exercise and nutrition interventions to improve muscle outcomes in older people. Clin Interv Aging 2015;10:859-69.
187. Menon MK, Houchen L, Singh SJ, et al. Inflammatory and satellite cells in the quadriceps of patients with COPD and response to resistance training. Chest 2012;142:1134-42.
188. Barreiro E, Ferrer D, Sanchez F, et al. Inflammatory cells and apoptosis in respiratory and limb muscles of patients with COPD. J Appl Physiol (1985) 2011;111:808-17.
189. Crul T, Spruit MA, Gayan-Ramirez G, et al. Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. Eur J Clin Invest 2007;37:897-904.
190. Fermoselle C, Rabinovich R, Ausín P, et al. Does oxidative stress modulate limb muscle atrophy in severe COPD patients? Eur Respir J 2012;40:851-62.
191. Barreiro E. Protein carbonylation and muscle function in COPD and other conditions. Mass Spectrom Rev 2014;33:219-36.
192. Gouzi F, Abdellaoui A, Molinari N, et al. Fiber atrophy, oxidative stress, and oxidative fiber reduction are the attributes of different phenotypes in chronic obstructive pulmonary disease patients. J Appl Physiol (1985) 2013;115:1796-805.
193. Marin-Corral J, Minguella J, Ramírez-Sarmiento AL, et al. Oxidised proteins and superoxide anion production in the diaphragm of severe COPD patients. Eur Respir J 2009;33:1309-19.
194. Rabinovich RA, Ardite E, Mayer AM, et al. Training depletes muscle glutathione in patients with chronic obstructive pulmonary disease and low body mass index. Respiration 2006;73:757-61.
195. Wijnhoven HJ, Heunks LM, Geraedts MC, et al. Oxidative and nitrosative stress in the diaphragm of patients with COPD. Int J Chron Obstruct Pulmon Dis 2006;1:173-9.
196. Wijnhoven JH, Janssen AJ, van Kuppevelt TH, et al. Metabolic capacity of the diaphragm in patients with COPD. Respir Med 2006;100:1064-71.
197. Orozco-Levi M, Coronell C, Ramírez-Sarmiento A, et al. Injury of peripheral muscles in smokers with chronic obstructive pulmonary disease. Ultrastruct Pathol 2012;36:228-38.
198. Camillo CA, Burtin C, Hornikx M, et al. Physiological responses during downhill walking: A new exercise modality for subjects with chronic obstructive pulmonary disease? Chron Respir Dis 2015;12:155-64.
199. Martínez-Llorens J, Casadevall C, Lloreta J, et al. Activation of satellite cells in the intercostal muscles of patients with chronic obstructive pulmonary disease. Arch Bronconeumol 2008;44:239-44.
200. Thériault ME, Paré MÈ, Lemire BB, et al. Regenerative defect in vastus lateralis muscle of patients with chronic obstructive pulmonary disease. Respir Res 2014;15:35.
201. Pomiès P, Rodriguez J, Blaquière M, et al. Reduced myotube diameter, atrophic signalling and elevated oxidative stress in cultured satellite cells from COPD patients. J Cell Mol Med 2015;19:175-86.
202. Thériault ME, Paré MÈ, Maltais F, et al. Satellite cells senescence in limb muscle of severe patients with COPD. PLoS One 2012;7:e39124.
203. Agustí AG, Sauleda J, Miralles C, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:485-9.
204. Guo Y, Gosker HR, Schols AM, et al. Autophagy in locomotor muscles of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:1313-20.
205. Puig-Vilanova E, Ausin P, Martinez-Llorens J, et al. Do epigenetic events take place in the vastus lateralis of patients with mild chronic obstructive pulmonary disease? PLoS One 2014;9:e102296.
206. Puig-Vilanova E, Martínez-Llorens J, Ausin P, et al. Quadriceps muscle weakness and atrophy are associated with a differential epigenetic profile in advanced COPD. Clin Sci (Lond) 2015;128:905-21.
207. Jatta K, Eliason G, Portela-Gomes GM, et al. Overexpression of von Hippel-Lindau protein in skeletal muscles of patients with chronic obstructive pulmonary disease. J Clin Pathol 2009;62:70-6.
208. Jobin J, Maltais F, Doyon JF, et al. Chronic obstructive pulmonary disease: capillarity and fiber-type characteristics of skeletal muscle. J Cardiopulm Rehabil 1998;18:432-7.
209. Saey D, Michaud A, Couillard A, et al. Contractile fatigue, muscle morphometry, and blood lactate in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:1109-15.
210. Vogiatzis I, Terzis G, Stratakos G, et al. Effect of pulmonary rehabilitation on peripheral muscle fiber remodeling in patients with COPD in GOLD stages II to IV. Chest 2011;140:744-52.
211. Green HJ, Burnett ME, D'Arsigny C, et al. Muscle fiber type characteristics in females with chronic obstructive pulmonary disease. A preliminary study. J Mol Histol 2009;40:41-51.
212. Jiménez-Fuentes MA, Gea J, Aguar MC, et al. Capillary density and respiratory function in the external intercostal muscle. Arch Bronconeumol 1999;35:471-6.
213. Orozco-Levi M, Gea J, Aguar MC, et al. Changes in the capillary content in the diaphragm of COPD patients: a sort of muscle remodelling? Am J Respir Crit Care Med 1996;153:A298.
214. Alexopoulou C, Mitrouska I, Arvanitis D, et al. Vascular-specific growth factor mRNA levels in the human diaphragm. Respiration 2005;72:636-41.
215. Poole DC, Mathieu-Costello O. Effect of pulmonary emphysema on diaphragm capillary geometry. J Appl Physiol (1985) 1997;82:599-606.
216. de Theije CC, Langen RC, Lamers WH, et al. Differential sensitivity of oxidative and glycolytic muscles to hypoxia-induced muscle atrophy. J Appl Physiol (1985) 2015;118:200-11.
217. Gosker HR, Hesselink MK, Duimel H, et al. Reduced mitochondrial density in the vastus lateralis muscle of patients with COPD. Eur Respir J 2007;30:73-9.
218. Meyer A, Zoll J, Charles AL, et al. Skeletal muscle mitochondrial dysfunction during chronic obstructive pulmonary disease: central actor and therapeutic target. Exp Physiol 2013;98:1063-78.
219. Levine S, Gregory C, Nguyen T, et al. Bioenergetic adaptation of individual human diaphragmatic myofibers to severe COPD. J Appl Physiol (1985) 2002;92:1205-13.
220. Ribera F, N'Guessan B, Zoll J, et al. Mitochondrial electron transport chain function is enhanced in inspiratory muscles of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:873-9.
221. Sanchez J, Brunet A, Medrano G, et al. Metabolic enzymatic activities in the intercostal and serratus muscles and in the latissimus dorsi of middle-aged normal men and patients with moderate obstructive pulmonary disease. Eur Respir J 1988;1:376-83.
222. Sánchez J, Bastien C, Medrano G, et al. Metabolic enzymatic activities in the diaphragm of normal men and patients with moderate chronic obstructive pulmonary disease. Bull Eur Physiopathol Respir 1984;20:535-40.
223. Maltais F, LeBlanc P, Whittom F, et al. Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with COPD. Thorax 2000;55:848-53.
224. Saey D, Lemire BB, Gagnon P, et al. Quadriceps metabolism during constant workrate cycling exercise in chronic obstructive pulmonary disease. J Appl Physiol (1985) 2011;110:116-24.
225. Sauleda J, García-Palmer F, Wiesner RJ, et al. Cytochrome oxidase activity and mitochondrial gene expression in skeletal muscle of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1413-7.
226. Crul T, Testelmans D, Spruit MA, et al. Gene expression profiling in vastus lateralis muscle during an acute exacerbation of COPD. Cell Physiol Biochem 2010;25:491-500.
227. Gosker HR, Zeegers MP, Wouters EF, et al. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax 2007;62:944-9.
228. Doucet M, Debigaré R, Joanisse DR, et al. Adaptation of the diaphragm and the vastus lateralis in mild-to-moderate COPD. Eur Respir J 2004;24:971-9.
229. Maltais F, Sullivan MJ, LeBlanc P, et al. Altered expression of myosin heavy chain in the vastus lateralis muscle in patients with COPD. Eur Respir J 1999;13:850-4.
230. Patel MS, Natanek SA, Stratakos G, et al. Vastus lateralis fiber shift is an independent predictor of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014;190:350-2.
231. Gosker HR, Engelen MP, van Mameren H, et al. Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr 2002;76:113-9.
232. Orozco-Levi M, Gea J, Sauleda J, et al. Structure of the latissimus dorsi muscle and respiratory function. J Appl Physiol (1985) 1995;78:1132-9.
233. Testelmans D, Crul T, Maes K, et al. Atrophy and hypertrophy signalling in the diaphragm of patients with COPD. Eur Respir J 2010;35:549-56.
234. Stubbings AK, Moore AJ, Dusmet M, et al. Physiological properties of human diaphragm muscle fibres and the effect of chronic obstructive pulmonary disease. J Physiol 2008;586:2637-50.
235. Engelen MP, Orozco-Levi M, Deutz NE, et al. Glutathione and glutamate levels in the diaphragm of patients with chronic obstructive pulmonary disease. Eur Respir J 2004;23:545-51.
236. Brocca L, Pellegrino MA, Lameri E, et al. Contractile properties of single muscle fibres from human intercostal muscles. J Mus Res Cell Motil 2003;24:335.
237. Ottenheijm CA, Heunks LM, Sieck GC, et al. Diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:200-5.
238. Debigaré R, Côte CH, Hould FS, et al. In vitro and in vivo contractile properties of the vastus lateralis muscle in males with COPD. Eur Respir J 2003;21:273-8.
239. Morrison WL, Gibson JN, Scrimgeour C, et al. Muscle wasting in emphysema. Clin Sci (Lond) 1988;75:415-20.
240. Engelen MP, Deutz NE, Wouters EF, et al. Enhanced levels of whole-body protein turnover in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:1488-92.
241. Pouw EM, Schols AM, Deutz NE, et al. Plasma and muscle amino acid levels in relation to resting energy expenditure and inflammation in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:797-801.
242. Yoneda T, Yoshikawa M, Fu A, et al. Plasma levels of amino acids and hypermetabolism in patients with chronic obstructive pulmonary disease. Nutrition 2001;17:95-9.
243. Engelen MP, Wouters EF, Deutz NE, et al. Factors contributing to alterations in skeletal muscle and plasma amino acid profiles in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 2000;72:1480-7.
244. Jagoe RT, Engelen MP. Muscle wasting and changes in muscle protein metabolism in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003;46:52s-63s.
245. Costes F, Gosker H, Feasson L, et al. Impaired exercise training-induced muscle fiber hypertrophy and Akt/mTOR pathway activation in hypoxemic patients with COPD. J Appl Physiol (1985) 2015;118:1040-9.
246. Debigaré R, Côté CH, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. Am J Respir Crit Care Med 2001;164:1712-7.
247. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004;117:399-412.
248. Cai D, Frantz JD, Tawa NE Jr, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004;119:285-98.
249. Doucet M, Russell AP, Léger B, et al. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:261-9.
250. Plant PJ, Brooks D, Faughnan M, et al. Cellular markers of muscle atrophy in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2010;42:461-71.
251. Ottenheijm CA, Heunks LM, Li YP, et al. Activation of the ubiquitin-proteasome pathway in the diaphragm in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:997-1002.
252. Scott SV, Klionsky DJ. Delivery of proteins and organelles to the vacuole from the cytoplasm. Curr Opin Cell Biol 1998;10:523-9.
253. Supinski GS, Callahan LA. Caspase activation contributes to endotoxin-induced diaphragm weakness. J Appl Physiol (1985) 2006;100:1770-7.
254. Wagner PD. Skeletal muscles in chronic obstructive pulmonary disease: deconditioning, or myopathy? Respirology 2006;11:681-6.